Shares of Ironwood Pharmaceuticals Inc. (IRWD) - Get Report rose nearly 7% to $15.50 ahead of the market open on Monday, Aug. 21, after the Cambridge, Mass.-based firm secured U.S. Food and Drug Administration approval for hyperuricemia drug Duzallo.
Duzallo is an oral treatment for hyperuricemia associated with gout in patients that have not achieved target serum uric acid (sUA) levels with a medically appropriate daily dose of allopurinol alone. Ironwood said it expects Duzallo to be commercially available in the early part of the fourth quarter.
More of What's Trending on TheStreet:
- Amazon's Instant Pickup Service Shows Clearly Who Jeff Bezos Is Targeting Next
- Why the World Isn't Ending: Market Recon
- How You Can Make Easy Money on Apple's iPhone 8 Juggernaut
- Today's Solar Eclipse Could Cost Companies a Mind-Blowing $694 Million